Emerging research suggest Retatrutide , a dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may provide a promising advancement for obesity management . Preliminary https://getretatrutideaustralia.com/blog/retatrutide-weight-loss-revolution-2026